| DB ID | MyCo_1594 |
| Title | Serum galactomannan levels in the diagnosis of invasive aspergillosis |
| Year | 2015 |
| PMID | 26552466 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | niger |
| Organism | Aspergillus niger |
| Ethical Statement | The Institutional Ethics Committee approved the study. |
| Site of Infection | Lungs |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Turkey |
| Cohort | One hundred sixty-five consecutive febrile neutropenia episodes of 106 hematologic malignancy patients be-tween the ages of 16 and 80 years, who had increased risk for IPA, were monitored proactively (except who under¬went hematopoietic stem cell transplantation). Patients whose serum samples were collected twice a week start¬ing on day 1 of their hospitalization but were lost due to other reasons before having fever and those whose consent could not be obtained were excluded from the study. |
| Cohort No. | 106 |
| Age Group | 18-80 |
| P Value | None |
| Sensitivity | 0.867 |
| Specificity | 0.718 |
| Positive Predictive Value | 0.351 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Despite the recent developments in the treatment of pa¬tients with hematologic malignancies who underwent hematopoietic stem cell transplantation and are under¬going heavy cytotoxic chemotherapy, invasive aspergil¬losis (IA) is still a significant cause of mortality. IA can cause invasive infection in many tissues/organs such as heart, brain, sinus, eye, skin, and ear. With increased use of immunosuppressive agents in recent years, inva¬sive pulmonary aspergillosis (IPA) incidence rates have increased up to 30% in some centers. Because the clinical symptoms of this infection are similar to those of other infectious diseases, the diagnosis is difficult. Moreover, since these patients are neutropenic, difficul¬ties are experienced in the follow-up of these patients’ response to the treatment as well. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit (ELISA; Platelia Aspergillus, Sanofi Diagnostics Pas¬teur, Marnes-La-Coquett, France) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
